Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | BRD1 | O95696 | 3/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.35 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353459 | 0.85 | SCN7A (0.41) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL27759451 | 0.82 | KCNH2 (0.47) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL19212693 | 0.79 | KCNH2 (0.40) | KCNH2CDC7BRD4 | |
| SCHEMBL4297734 | 0.78 | KDM4E (0.41) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3409318 | 0.78 | HDAC1 (0.40) | KMOCCR9BRPF1BRD4BRD9 | |
| SCHEMBL4779522 | 0.76 | SCN7A (0.58) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL19211607 | 0.76 | KCNH2 (0.43) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3777387 | 0.75 | SCN7A (0.48) | KCNH2SCN7AKMOMAPK8MAPK9 | |
| SCHEMBL29456187 | 0.75 | SCN7A (0.48) | KCNH2SCN7AKMOMAPK8MAPK9 | |
| SCHEMBL19212650 | 0.75 | SCN7A (0.48) | KCNH2SCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055266-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2019-02-21 | — | — | US | disclosed |
| CN-109121397-A | Heterocyclic compound, especially 2- oxo -4,4,5,5,6,6,7,7- octahydro benzoxazoles derivatives and their purposes as antimicrobial compound | 莱德克斯制药公共有限公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-3413976-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137744-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055266-A1 | HETEROCYCLIC COMPOUNDS, IN PARTICULAR 2-OXO-4,4,5,5,6,6,7,7-OCTAHYDROBENZOXAZOLE DERIVATIVES, AND THEIR USE AS ANTIBACTERIAL COMPOUNDS | OXA1L, OGFOD1, OCIAD2 | KCNH2 1227/4885SCN7A 2102/4885SCN5A 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.